CTRI/2024/07/070026
Recruiting
未知
Clinical evaluation of effect of metronomic chemotherapy in cachexia associated with triple negative breast cancer. - NI
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Health Condition 1: C509- Malignant neoplasm of breast of unspecified site
- Sponsor
- A
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\) Female patients with age more than equal to 18 years and less than equal to 80 years.
- •2\) Patients with confirmed TNBC from pathological reports, previously treated or not with other drugs for the metastatic disease.
- •3\) Patients with more than equal to 1 measurable lesion according to RECIST 1\.1 criteria, ECOG score less than equal to 2 and life expectancy of more than equal to 16 weeks.
- •4\) Patients with adequate bone marrow, hepatic, and renal functions, indicated by haemoglobin more than equal to 10g per L, absolute neutrophil count more than equal to 1\.5 billion neutrophils per liter of blood, platelet count more than equal to 100 billion platelets per liter of blood, total serum bilirubin less than 1\.5 of upper normal limit (UNL), AST/ALT less than 2\.5 of UNL, (less than 3\.5 of UNL for liver metastases), or alkaline phosphatase less than 2\.5 of UNL (less than 5 of UNL for bone/liver metastases).
- •5\) Evidence of cachexia as judged by one of:
- •a. More than equal to 5 percent of documented weight loss in the previous 6 months.
- •b. A subjective report of weight loss in the previous 6 months and a recorded BMI less than 20 kilograms per square meter.
- •c. Ongoing documented weight loss of at least 1 kg in the week prior to day 0; or 1\.25 kg in the 2 weeks prior to day 0, or 1\.5 kg in the 3 to 6 weeks prior to day 0; provided that BMI is not more than 25 kilograms per square meter.
Exclusion Criteria
- •1\)Patients not ready to provide written informed consent.
- •2\)Patient with other severe co\-morbidities like renal or hepatic complications, cardiac disease, uncontrolled diabetes or hypercalcemia, severe peripheral neuropathy, active infection, or previous organ allograft.
- •3\)Patients with history of another malignancy.
- •4\)Patients unable to swallow pills or gastrointestinal conditions that might predispose to drug intolerability or poor drug absorption.
- •5\)Pregnant or lactating women.
- •6\)Patients with history of hypersensitivity to any of the regimen to be used in capecitabine, methotrexate and cyclophosphamide.
- •7\)Women who had participated in another clinical trial with any investigational drug within 30 days before study inclusion.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Metronomic chemotherapy in elderly non-fit patients with aggressive B-Cell lymphomas. Phase II studyB-Cell lymphomasMedDRA version: 21.0Level: LLTClassification code 10012855Term: Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation)System Organ Class: 100000004864Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]EUCTR2016-003703-62-ITFONDAZIONE ITALIANA LINFOMI ONLUS60
Active, not recruiting
Not Applicable
A phase II study evaluating the role of the combination of Vinorelbine,cyclophosphamide and capecitabine administered metronomically, that means low doses daily orally, in patients with advanced breast cancerMetastatic breast cancerMedDRA version: 14.1Level: PTClassification code 10055113Term: Breast cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2010-024266-21-ITISTITUTO EUROPEO DI ONCOLOGIA100
Active, not recruiting
Not Applicable
A phase II study of metronomic oral chemotherapy with cyclophosphamide plus capecitabine combined with bevacizumab and erlotinib (BEXE), plus trastuzumab in HER2/neu positive tumors (BEXET), in advanced breast canceradvanced or metastatic breast cancerMedDRA version: 14.1Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2007-006025-27-ITISTITUTO EUROPEO DI ONCOLOGIA
Active, not recruiting
Not Applicable
A phase II study of metronomic oral chemoterapy with Cyclophosphamide plus Capecitabine combined with Trastuzumab in advanced breast cancer - NDPre-or post-menopausal women with histologically proven, locally advanced (inoperable) or metastatic breast cancer.EUCTR2009-017083-16-ITGOIM GRUPPO ONCOLOGICO MERIDIONALE
Not yet recruiting
Phase 4
comparative evaluation chemicomechanical caries removal by atraumatic restorative treatment and by conventional carbide burHealth Condition 1: K026- Dental caries on smooth surfaceCTRI/2024/03/064008Drsheetal schavan